New Drug Product: Imbruvica

Treatment of patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

Biking, Prostate Cancer Risk Investigated

Cyclists who bike more may face a higher risk of prostate cancer, but not a greater chance of infertility or erectile dysfunction.

Could Statins Cut Breast Cancer Risk?

Women with hyperlipidemia have an increased risk of developing breast cancer, according to a new study.

Vaccine-Chemo for Pancreatic Cancer

The results of a new trial are extremely promising for the efficacy of a vaccine-chemotherapy combination for pancreatic cancer.

Novel Gene Mutations and Lung Cancer

Researchers have identified genetic mutations in the cell signaling pathway RTK/RAS/RAF that can lead to lung adenocarcinoma.

Corticosteroids for Cancer Pain?

Even with limited evidence as to their efficacy, corticosteroids are often included in cancer pain management therapy.

No Fertility Drug-Cancer Link

Use of fertility drugs doesn't appear to increase a woman's long-term risk of breast, ovarian, and uterine cancers, new research indicates.

Prostate Cancer Treatments

Review this new chart on FDA-approved prostate cancer treatments for quick information when you need it.

News

Diabetes, Head and Neck Cancer Risk Linked in Study

Diabetes, Head and Neck Cancer Risk Linked in Study

Patients newly diagnosed with diabetes have an increased risk of developing head and neck cancer, according to a new study.

Physician Trust Impacts Cancer Patient Distress, Physical Limitations

Physician Trust Impacts Cancer Patient Distress, Physical Limitations

Having a lower level of trust in one's physician is associated with more emotional distress and more physical limitations within the first 15 months after cancer diagnosis in more anxiously attached patients.

Expanded Use of Imbruvica Approved

Expanded Use of Imbruvica Approved

The FDA has approved the expanded use of Imbruvica (ibrutinib; Pharmacyclics and Janssen Biotech) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion).

HPV Test Every 3 Years Better Than Pap Test

HPV Test Every 3 Years Better Than Pap Test

Primary human papillomavirus (HPV) testing every three years seems to be a better screening alternative to Papanicolaou (Pap) testing every three years or concurrent HPV and Pap testing every five years.

Charts

Make prescribing decisions with our comparative charts and treatment algorithms.

Calculators

Quickly and accurately perform clinical calculations.

Patient Information Fact Sheets

Download or print easy-to-read disease leaflets for your patients.

Featured courses from mycme

The Brigham Board Review in Hematology and OncologyExternal web site

The Brigham Board Review in Hematology and Oncology offers expert preparation for your ABIM subspecialty ...

CME 42.00 Credits

Understanding Current and Emerging Therapies for Head and Neck CancersExternal web site

This activity can help oncology nurses refresh their knowledge of the risks and treatments for ...

CE 0.50 Credits

Vertebroplasty is effective for managing myelomatous VCFsExternal web site

Nurse awareness of this treatment option and the patient selection criteria may be a significant ...

CE 0.60 Credits

Sign Up for Free e-newsletters